171 related articles for article (PubMed ID: 18093255)
1. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.
Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
Br J Clin Pharmacol; 2008 May; 65(5):667-73. PubMed ID: 18093255
[TBL] [Abstract][Full Text] [Related]
2. Differential bidirectional transfer of indinavir in the isolated perfused human placenta.
Sudhakaran S; Ghabrial H; Nation RL; Kong DC; Gude NM; Angus PW; Rayner CR
Antimicrob Agents Chemother; 2005 Mar; 49(3):1023-8. PubMed ID: 15728898
[TBL] [Abstract][Full Text] [Related]
3. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors.
Profit L; Eagling VA; Back DJ
AIDS; 1999 Sep; 13(13):1623-7. PubMed ID: 10509562
[TBL] [Abstract][Full Text] [Related]
4. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
5. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines.
Ronaldson PT; Lee G; Dallas S; Bendayan R
Pharm Res; 2004 May; 21(5):811-8. PubMed ID: 15180339
[TBL] [Abstract][Full Text] [Related]
6. Functional role of P-glycoprotein in the human blood-placental barrier.
Mölsä M; Heikkinen T; Hakkola J; Hakala K; Wallerman O; Wadelius M; Wadelius C; Laine K
Clin Pharmacol Ther; 2005 Aug; 78(2):123-31. PubMed ID: 16084847
[TBL] [Abstract][Full Text] [Related]
7. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients.
Solas C; Simon N; Drogoul MP; Quaranta S; Frixon-Marin V; Bourgarel-Rey V; Brunet C; Gastaut JA; Durand A; Lacarelle B; Poizot-Martin I
Br J Clin Pharmacol; 2007 Sep; 64(3):353-62. PubMed ID: 17517050
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Hoetelmans RM; Beijnen JH; Schinkel AH
Mol Pharmacol; 2001 Apr; 59(4):806-13. PubMed ID: 11259625
[TBL] [Abstract][Full Text] [Related]
9. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
10. HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.
Lucia MB; Rutella S; Leone G; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):321-30. PubMed ID: 11468419
[TBL] [Abstract][Full Text] [Related]
11. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells.
Washington CB; Duran GE; Man MC; Sikic BI; Blaschke TF
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Nov; 19(3):203-9. PubMed ID: 9803961
[TBL] [Abstract][Full Text] [Related]
12. Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: Effect on transplacental disposition in rats.
Cerveny L; Ptackova Z; Durisova M; Staud F
Reprod Toxicol; 2018 Aug; 79():57-65. PubMed ID: 29859254
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Mechanism and Extent of Transplacental Transfer of (-)-∆
Kumar AR; Sheikh ED; Monson JW; Ligon SE; Talley RL; Dornisch EM; Howitz KJ; Damicis JR; Ieronimakis N; Unadkat JD
Clin Pharmacol Ther; 2023 Aug; 114(2):446-458. PubMed ID: 37278090
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
Kappelhoff BS; Huitema AD; Sankatsing SU; Meenhorst PL; Van Gorp EC; Mulder JW; Prins JM; Beijnen JH
Br J Clin Pharmacol; 2005 Sep; 60(3):276-86. PubMed ID: 16120066
[TBL] [Abstract][Full Text] [Related]
15. Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals.
McCormack SA; Best BM
Clin Pharmacokinet; 2014 Nov; 53(11):989-1004. PubMed ID: 25223699
[TBL] [Abstract][Full Text] [Related]
16. Lack of interaction of digoxin and P-glycoprotein inhibitors, quinidine and verapamil in human placenta in vitro.
Holcberg G; Sapir O; Tsadkin M; Huleihel M; Lazer S; Katz M; Mazor M; Ben-Zvi Z
Eur J Obstet Gynecol Reprod Biol; 2003 Aug; 109(2):133-7. PubMed ID: 12860328
[TBL] [Abstract][Full Text] [Related]
17. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
Huisman MT; Smit JW; Crommentuyn KM; Zelcer N; Wiltshire HR; Beijnen JH; Schinkel AH
AIDS; 2002 Nov; 16(17):2295-301. PubMed ID: 12441801
[TBL] [Abstract][Full Text] [Related]
18. P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?
Jones K; Bray PG; Khoo SH; Davey RA; Meaden ER; Ward SA; Back DJ
AIDS; 2001 Jul; 15(11):1353-8. PubMed ID: 11504956
[TBL] [Abstract][Full Text] [Related]
19. The effect of probenecid and MK-571 on the feto-maternal transfer of saquinavir in dually perfused human term placenta.
Rahi MM; Heikkinen TM; Hakala KE; Laine KP
Eur J Pharm Sci; 2009 Jul; 37(5):588-92. PubMed ID: 19454316
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.
Shiraki N; Hamada A; Yasuda K; Fujii J; Arimori K; Nakano M
Biol Pharm Bull; 2000 Dec; 23(12):1528-31. PubMed ID: 11145192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
